Roy Buchanan
Stock Analyst at JMP Securities
(1.02)
# 3,625
Out of 4,761 analysts
50
Total ratings
33.33%
Success rate
-20.22%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVAC CureVac | Reiterates: Market Outperform | $16 | $3.30 | +384.85% | 8 | Feb 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $56.63 | - | 1 | Feb 13, 2025 | |
| ANTX AN2 Therapeutics | Reiterates: Market Outperform | $5 | $1.13 | +342.48% | 6 | Feb 3, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $1.82 | +671.35% | 1 | Jan 30, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 | $1.82 | +284.62% | 2 | Jan 23, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $2.24 | +703.57% | 2 | Jan 10, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $8.08 | +308.42% | 1 | Jan 10, 2025 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Outperform | $22 → $21 | $8.03 | +161.52% | 11 | Nov 26, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Market Outperform | $24 → $7 | $1.78 | +293.26% | 2 | Nov 21, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Market Outperform | $4 → $5 | $3.42 | +46.20% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $27 | $13.33 | +102.55% | 5 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $644.48 | -30.49% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $10.13 | +57.95% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.48 | - | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $420 | $2.99 | +13,946.82% | 1 | Sep 14, 2021 |
CureVac
Feb 14, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $3.30
Upside: +384.85%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $56.63
Upside: -
AN2 Therapeutics
Feb 3, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $1.13
Upside: +342.48%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $1.82
Upside: +671.35%
Esperion Therapeutics
Jan 23, 2025
Reiterates: Market Outperform
Price Target: $7
Current: $1.82
Upside: +284.62%
Inovio Pharmaceuticals
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.24
Upside: +703.57%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $8.08
Upside: +308.42%
Enanta Pharmaceuticals
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22 → $21
Current: $8.03
Upside: +161.52%
HOOKIPA Pharma
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $1.78
Upside: +293.26%
Arbutus Biopharma
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.42
Upside: +46.20%
Nov 3, 2023
Maintains: Market Outperform
Price Target: $25 → $27
Current: $13.33
Upside: +102.55%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $644.48
Upside: -30.49%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $10.13
Upside: +57.95%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.48
Upside: -
Sep 14, 2021
Initiates: Market Outperform
Price Target: $420
Current: $2.99
Upside: +13,946.82%